# A Multicenter Prospective Study of Iptacopan in the Treatment of Refractory/Relapsed Autoimmune Hemolytic Anemia (AIHA)

> **NCT06847607** · NA · NOT_YET_RECRUITING · sponsor: **Bing Han** · enrollment: 20 (estimated)

## Conditions studied

- AIHA - Warm Autoimmune Hemolytic Anemia
- AIHA - Cold Autoimmune Hemolytic Anemia

## Interventions

- **DRUG:** Iptacopan

## Key facts

- **NCT ID:** NCT06847607
- **Lead sponsor:** Bing Han
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-03-01
- **Primary completion:** 2025-10-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06847607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06847607, "A Multicenter Prospective Study of Iptacopan in the Treatment of Refractory/Relapsed Autoimmune Hemolytic Anemia (AIHA)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06847607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*